Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4451
Corbus Pharmaceuticals
CRBP
$119M
| $120K | ﹤0.01% |
14,758
+10,874
| +280% | +$134K |
2024 Q1
7 quarters
|
|
4452
Golub Capital BDC
GBDC
$3.26B
| $120K | ﹤0.01% |
+8,852
| New | +$123K |
2025 Q4
0 quarters
|
|
4453
TMC The Metals Company
TMC
$1.67B
| $120K | ﹤0.01% |
19,431
+14,668
| +308% | +$103K |
2023 Q1
11 quarters
|
|
4454
Cadeler
CDLR
$2.14B
| $119K | ﹤0.01% |
+6,423
| New | +$120K |
2025 Q4
0 quarters
|
|
4455
PUT
Arcus Biosciences
RCUS
$3.11B
| $119K | ﹤0.01% |
+5,000
| New | +$102K |
2025 Q4
0 quarters
|
|
|
GOOS
4456
Canada Goose Holdings
GOOS
$748M
| $119K | ﹤0.01% |
9,193
-398,405
| -98% | -$5.3M |
2017 Q4
32 quarters
|
|
4457
Microbot Medical
MBOT
$77.9M
| $119K | ﹤0.01% |
59,377
+59,376
| +5,937,600% | +$141K |
2015 Q4
40 quarters
|
|
4458
American Well
AMWL
$211M
| $118K | ﹤0.01% |
24,047
+9,705
| +68% | +$46.8K |
2022 Q1
15 quarters
|
|
4459
CALL
TotalEnergies
TTE
$186B
| $118K | ﹤0.01% |
+1,800
| New | +$114K |
2025 Q4
0 quarters
|
|
4460
Lakeland Industries
LAKE
$102M
| $117K | ﹤0.01% |
13,289
+388
| +3% | +$5.45K |
2024 Q3
5 quarters
|
|
4461
BARK
BARK
$73.4M
| $116K | ﹤0.01% |
9,641
-108
| -1% | -$1.6K |
2022 Q1
15 quarters
|
|
|
FSP
4462
Franklin Street Properties
FSP
$34.3M
| $116K | ﹤0.01% |
122,577
+11,489
| +10% | +$13.4K |
2013 Q2
50 quarters
|
|
4463
ReNew
RNW
$2.49B
| $115K | ﹤0.01% |
20,409
| – | – |
2024 Q2
6 quarters
|
|
|
MAPS
4464
DELISTED
WM TECHNOLOGY INC A
MAPS
| $115K | ﹤0.01% |
139,680
+14,844
| +12% | +$14.6K |
2024 Q2
6 quarters
|
|
|
ZFEB
4465
Innovator Equity Defined Protection ETF - 1 Yr February
ZFEB
$151M
| $115K | ﹤0.01% |
4,536
-3,501
| -44% | -$87.9K |
2025 Q2
2 quarters
|
|
4466
BRC Group Holdings
RILY
$195M
| $115K | ﹤0.01% |
24,609
+17,274
| +236% | +$85.5K |
2016 Q3
37 quarters
|
|
4467
AbCellera Biologics
ABCL
$4.45B
| $115K | ﹤0.01% |
33,547
+2,649
| +9% | +$11.8K |
2022 Q1
15 quarters
|
|
4468
Innovator US Equity Buffer ETF September
BSEP
$465M
| $114K | ﹤0.01% |
+2,319
| New | +$113K |
2025 Q4
0 quarters
|
|
4469
Playboy Inc
PLBY
$125M
| $114K | ﹤0.01% |
60,651
+59,710
| +6,345% | +$97.6K |
2025 Q3
1 quarter
|
|
4470
Cellebrite
CLBT
$2.78B
| $114K | ﹤0.01% |
6,305
+3,582
| +132% | +$64.3K |
2023 Q2
10 quarters
|
|
4471
Virco
VIRC
$103M
| $113K | ﹤0.01% |
17,665
+2,495
| +16% | +$17.4K |
2024 Q2
6 quarters
|
|
|
XAPR
4472
FT Vest U.S. Equity Enhance & Moderate Buffer ETF - April
XAPR
$33.9M
| $113K | ﹤0.01% |
3,095
-1,922
| -38% | -$69.3K |
2024 Q3
5 quarters
|
|
|
VSNT
4473
Versant Media Group
VSNT
$4.31B
| $113K | ﹤0.01% |
+2,500
| New | +$116K |
2025 Q4
0 quarters
|
|
4474
Instil Bio
TIL
$49M
| $112K | ﹤0.01% |
10,145
+3,995
| +65% | +$59.1K |
2024 Q1
7 quarters
|
|
|
MNTN
4475
MNTN Inc
MNTN
$740M
| $111K | ﹤0.01% |
9,326
+8,944
| +2,341% | +$129K |
2025 Q3
1 quarter
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.